E-cigarettes a Legitimate Tool for Smoking Cessation: Study

Aug.25.2022
E-cigarettes a Legitimate Tool for Smoking Cessation: Study
Australian study finds that e-cigarettes are a legitimate tool for adult smokers to quit smoking.

An Australian research team has extracted data from the 2019 National Drug Strategy Household Survey and analyzed the relationship between 3,868 adult smokers in Australia who use e-cigarettes and smoking cessation. The conclusion drawn is that e-cigarettes are a legitimate smoking cessation tool for adult smokers.


A recent study suggests that daily smokers are more likely to reduce their cigarette intake and quit smoking altogether compared to those who do not use e-cigarettes. Smokers over the past year are also more likely to quit smoking. However, occasional reduction of e-cigarette use and quitting smoking show no significant difference from those who do not use e-cigarettes.


Despite Australia's hostile attitude towards electronic cigarettes, in 2020, the Royal Australian College of General Practitioners (RACGP) announced its recommendation to use nicotine-containing electronic cigarette products for smoking cessation.


In the latest update of the national smoking cessation guidelines, general practitioners have stated that they have been conducting thorough reviews of the effectiveness and safety of e-cigarettes and have concluded that they are a legitimate cessation aid for adult smokers.


Last year, the recommendation to continue banning the importation of any nicotine-containing e-cigarette oil by Australian Federal Health Minister Greg Hunt was overlooked. Several months later, the Therapeutic Goods Administration (TGA) announced their final decision: "Importing nicotine e-cigarettes requires a doctor's prescription.


As of October 2021, Australia only allows the purchase of e-cigarette products from pharmacies through a prescription. While neighboring New Zealand and most other countries allow retailers to sell nicotine products over-the-counter, anyone found violating Australia's strict regulations will face hefty fines and, in some cases, even imprisonment.


A spokesperson for the TGA explained that such criminal offenses could result in civil penalties and fines, with individuals facing a maximum fine of 5,000 penalty units, equating to a maximum of $111,000, and companies facing a maximum fine of 50,000 penalty units, equating to a maximum of $11.1 million.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the viewpoint of 2FIRSTS and the company is unable to confirm the authenticity and accuracy of its content. The compilation of this article is intended for industry discussion and research purposes only.


Due to limitations in the level of translation, the translated article may not fully convey the meaning of the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in relation to any domestic, Hong Kong, Macao, Taiwan and foreign-related remarks and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.
Feb.26
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
Before the Boom:  Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
Before the Boom: Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
As the U.S. nicotine pouch market moves toward regulatory clarity and rapid growth, attention is shifting from demand to execution. In an interview with 2Firsts, U.S.-based manufacturer Rena explains why manufacturing capacity, quality systems, and compliance readiness are becoming decisive factors before the market fully takes off.
Jan.19